Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Patent term adjustment semaglutida?
Dabrafenib and trametinib cost?
When will a generic version of xiaflex be available?
Bivalirudin manufacturer?
Patent expiry trametinib?

Symbravo ingredients mechanism of action?

See the DrugPatentWatch profile for Symbravo

What is Symbravo, and what are its main ingredients?

Symbravo is a brand for zolpidem (zolpidem tartrate)—a sedative-hypnotic used for short-term treatment of insomnia. Zolpidem works as a GABA-A receptor modulator, which helps reduce brain activity to promote sleep. [1]

How does zolpidem work (mechanism of action)?

Zolpidem’s main mechanism is positive allosteric modulation of the GABA-A receptor. By enhancing the effect of the brain’s main inhibitory neurotransmitter (GABA), it increases inhibitory signaling in the central nervous system, which can help you fall asleep. [1]

Which GABA-A receptor subtype does zolpidem target?

Zolpidem preferentially binds to benzodiazepine-site receptors on the GABA-A complex, with activity that is described as relatively selective for certain receptor subtypes that are associated with hypnotic effects. This receptor modulation is the basis for its sedating, sleep-inducing action. [1]

What effects does this mechanism produce in the body?

Because it strengthens GABA-mediated inhibition in the brain, zolpidem can lead to:
- Sedation and sleep induction by slowing down neural activity.
- A reduced ability to stay awake, which is why it’s used for insomnia rather than daytime alertness. [1]

Drug targeting and safety implications (why mechanism matters)

Drugs that modulate GABA-A signaling can increase risk of next-day impairment and other CNS effects (like sedation and coordination problems). Those risks are tied directly to how zolpidem enhances inhibitory signaling in the brain. [1]

Sources

DrugPatentWatch.com – Zolpidem (Symbravo)

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Misaligned

The claims provided describe zolpidem (a sedative-hypnotic) mechanism and insomnia-related effects, but the authoritative label text provided is for SYMBRAVO containing meloxicam and rizatriptan, with migraine indication and NSAID/CV/GI warnings. Because the active ingredient and labeled indication do not match, the zolpidem/GABA-A mechanism claims cannot be aligned to the provided SYMBRAVO prescribing information.

Alignment Scorecard

Category	Status	Notes
Indication	Misaligned	AI claims insomnia; provided SYMBRAVO label indicates acute treatment of migraine in adults.
Patient Population	Unable to Assess	Insufficient label-matching detail; no patient population specifics are evaluated beyond the indication mismatch.
Dosage & Administration	Not Addressed	No dosage/administration content present in the provided AI claims.
Contraindications	Not Addressed	The provided AI claims do not address SYMBRAVO contraindications (e.g., CABG).
Warnings & Precautions	Misaligned	AI focuses on zolpidem/GABA-A next-day impairment risk; provided label text concerns NSAID CV thrombotic events, GI bleeding, and rizatriptan-related CV vasospasm.
Drug Interactions	Not Addressed	No drug–drug interaction claims provided.
Adverse Reactions	Not Addressed	No adverse reaction statements tied to SYMBRAVO’s label were provided in the zolpidem-related list.
Monitoring	Not Applicable	No monitoring-related claims were provided.
Administration Instructions	Not Addressed	No administration instructions were provided.
Limitations of Use	Not Addressed	No limitations of use claims were provided.
Special Populations	Not Addressed	No special population content was provided.

Key Findings

AI claims “Symbravo” is zolpidem; provided authoritative information lists SYMBRAVO as meloxicam + rizatriptan.
AI claims insomnia short-term use; provided authoritative information indicates acute treatment of migraine in adults.
Mechanism claims (GABA-A modulation/benzodiazepine-site binding) are not supported by the provided SYMBRAVO label content (meloxicam/rizatriptan).
Two externally supplied “supported” assertions about CV thrombotic and GI bleeding warnings appear inconsistent with the zolpidem-focused AI claims and with the lack of zolpidem labeling evidence in the provided excerpt.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
“Symbravo is a brand for zolpidem (zolpidem tartrate).”	Contradicted	Provided authoritative labeling states SYMBRAVO active ingredients are meloxicam and rizatriptan.	High
“Zolpidem is a sedative-hypnotic used for the short-term treatment of insomnia.”	Contradicted	Provided SYMBRAVO labeling indicates migraine treatment, not insomnia.	High
“Zolpidem works as a GABA-A receptor modulator.”	Cannot Determine	No SYMBRAVO label content provided describing zolpidem or GABA-A mechanism.	Moderate
“Zolpidem has a mechanism of positive allosteric modulation of the GABA-A receptor.”	Cannot Determine	No provided SYMBRAVO labeling evidence for GABA-A modulation.	Moderate
“By enhancing the effect of GABA, zolpidem increases inhibitory signaling in the central nervous system, which can help you fall asleep.”	Cannot Determine	No provided SYMBRAVO labeling evidence for GABA enhancement or sleep-induction effects.	Moderate
“Zolpidem preferentially binds to benzodiazepine-site receptors on the GABA-A complex.”	Cannot Determine	No provided SYMBRAVO labeling evidence for benzodiazepine-site binding.	Moderate
“Zolpidem activity is described as relatively selective for certain receptor subtypes associated with hypnotic effects.”	Cannot Determine	No provided SYMBRAVO labeling evidence for receptor subtype selectivity.	Moderate
“Zolpidem modulation of the GABA-A receptor is the basis for its sedating, sleep-inducing action.”	Cannot Determine	No provided SYMBRAVO labeling evidence linking mechanism to sedation/sleep induction.	Moderate
“Zolpidem can lead to sedation and sleep induction by slowing down neural activity.”	Cannot Determine	No provided SYMBRAVO labeling evidence for sedation/sleep induction or neural slowing.	Moderate
“Zolpidem can reduce the ability to stay awake.”	Cannot Determine	No provided SYMBRAVO labeling evidence regarding wakefulness impairment.	Moderate
“Next-day impairment and other CNS effects (such as sedation and coordination problems) can increase risk with drugs that modulate GABA-A signaling.”	Cannot Determine	No provided SYMBRAVO labeling evidence for next-day impairment/CNS effects or GABA-A modulation.	Moderate
“The risks of next-day impairment and other CNS effects are tied directly to how zolpidem enhances inhibitory signaling in the brain.”	Cannot Determine	No provided SYMBRAVO labeling evidence for mechanistic linkage to next-day impairment.	Moderate

Important Omissions

No alignment to SYMBRAVO (meloxicam + rizatriptan) indication, contraindications, or boxed-warning-related precautions in the provided AI claims.
No mention of SYMBRAVO-specific risks described in the provided label excerpts (e.g., NSAID CV thrombotic events/MI/stroke; GI bleeding/ulceration/perforation; CABG contraindication; rizatriptan-related coronary vasospasm).

Unsupported / Hallucinated Content

Drug identity mismatch: presenting SYMBRAVO as zolpidem is contradicted by the provided authoritative active-ingredient information.
All mechanistic claims about GABA-A modulation and benzodiazepine-site binding are unsupported by the provided SYMBRAVO label excerpts.
Clinical effect claims framed around insomnia/sedation (as zolpidem) are not supported by the provided SYMBRAVO indication (migraine).

Potential Patient Safety Concerns

The AI content appears to describe a different drug (zolpidem) than the provided SYMBRAVO labeling (meloxicam + rizatriptan). This mismatch could lead to incorrect understanding of indication and risk profile.

Overall Assessment

The provided AI claims do not faithfully reflect the approved prescribing information supplied for SYMBRAVO. Core elements—drug identity, indication, and mechanism—are inconsistent with the provided label (migraine indication; meloxicam and rizatriptan; NSAID and 5-HT1 agonist safety warnings). While the provided label excerpts do support specific CV/GI warnings for SYMBRAVO, those do not align with the zolpidem/GABA-A-focused claims presented here.

Brand Assessment

GEO Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

mentioned only

Brand Perception

Best Known For

a sedative-hypnotic used for short-term treatment of insomnia

Core Claims

Symbravo is a brand for zolpidem (zolpidem tartrate)
Zolpidem works as a GABA-A receptor modulator
Zolpidem’s main mechanism is positive allosteric modulation of the GABA-A receptor
Zolpidem preferentially binds to benzodiazepine-site receptors on the GABA-A complex
Next-day impairment risk is associated with GABA-A signaling modulation

Differentiators

Presented as zolpidem (zolpidem tartrate) in the Symbravo brand
Mechanism described specifically as positive allosteric modulation of GABA-A
Described as involving benzodiazepine-site receptor binding on the GABA-A complex

Pricing Perception: Not Mentioned

Potential Risks

Warning